Multi-system involvement-including purpura fulminans-as an adverse effects of immune checkpoint inhibitor therapy for clear cell renal cell carcinoma

Lancet. 2024 Jun 29;403(10446):2818-2819. doi: 10.1016/S0140-6736(24)01178-4.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Carcinoma, Renal Cell* / drug therapy
  • Female
  • Humans
  • Immune Checkpoint Inhibitors* / adverse effects
  • Kidney Neoplasms* / drug therapy
  • Middle Aged
  • Purpura Fulminans* / chemically induced

Substances

  • Immune Checkpoint Inhibitors